Medivir AB (STO:MVIRB), announced today that four abstracts related to simeprevir (TMC435), have been accepted for presentation at the 63nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place from November 9-13 in Boston, USA.
Simeprevir is a once daily potent HCV NS3/4A protease inhibitor in phase III clinical development for the treatment of chronic hepatitis C jointly developed by Medivir and Janssen Research & Development Ireland (Janssen).
Two of the abstracts will be presented as oral presentations and two as posters at the Hynes Convention Center in Boston.
Parallel Session 12, HCV New Agents: Hard to Treat Patients, Hynes Ballroom B & C, November 11, 16:45-18:15
Clinical HCV 1, Poster Hall, November 11, 08:00-17:30
The abstracts have been published today and can be accessed on the AASLD website: http://www.aasld.org.
About Simeprevir (TMC435)
Simeprevir is a once daily potent HCV NS3/4A protease inhibitor jointly developed by Medivir and Janssen Research & Development Ireland (Janssen) to treat chronic hepatitis C virus infections.
Simeprevir is being developed both in combination with PegIFN/RBV and in combination with other Direct-acting Antiviral (DAA) agents in an all oral Interferon (IFN) free regimen, with or without Ribavirin (RBV).
Simeprevir is currently being evaluated in three global phase III studies, QUEST-1 and QUEST-2 in treatment-naÃ¯ve patients and PROMISE in patients who have relapsed after prior PegIFN/RBV-treatment. In parallel to these trials, phase III studies for simeprevir in Japan, in both treatment naive and treatment experienced hepatitis C genotype-1 infected patients, are ongoing.
In parallel with the ongoing global phase III-studies, simeprevir is currently in three phase II Interferon free trials with or without Ribavirin.
For additional information about simeprevir (TMC435) please see www.clinicaltrials.gov
About Hepatitis C
Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and liver transplants. The World Health Organization estimates that nearly 170 million people worldwide, or approximately 3% of the world's population, are infected with hepatitis C virus (HCV). The CDC (Centers for Disease Control and Prevention) has reported that more than three million people in the United States are chronically infected with HCV.
Medivir is an emerging research-based pharmaceutical company focused on infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Companyâ€™s key pipeline asset is simeprevir (TMC435), a novel protease inhibitor in phase III clinical development for hepatitis C that is being developed in collaboration with Janssen Research & Development Ireland.
In June 2011, Medivir acquired the specialty pharmaceutical company BioPhausia and today Medivir has a broad product portfolio with prescription pharmaceuticals in the Nordics.
Medivirâ€™s first product, the unique cold sore product XereseÂ®/XerclearÂ®, is launched in collaboration with GlaxoSmithKline to be sold OTC under the brand name ZoviDuo in Europe, Japan and Russia.
Medivirâ€™s IPO was in 1996 and currently the company has around 180 employees.
For more information about Medivir, please visit the Companyâ€™s website: www.medivir.com
Medivir is a collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C. We are passionate and uncompromising in our mission to develop and commercialize innovative pharmaceuticals that improve peopleâ€™s lives.
This information was brought to you by Cision http://www.cisionwire.comBusiness Wire
Last updated on: 01/10/2012 16:00:08